Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. April 2026 05:14 ET | Quelle: Research and Markets

Multiple Sclerosis Market Competitive Landscape Report 2026: Comprehensive Insights on Over 60 Companies and 75 Drugs by Product Type, Development Stage, Administration Route, and Molecule Type

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Multiple Sclerosis - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights...
13. April 2026 01:00 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly...
13. April 2026 01:00 ET | Quelle: Sanofi Winthrop Industrie

Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants

Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants L'approbation dans l'urticaire chronique spontanée...
13. April 2026 01:00 ET | Quelle: Sanofi Winthrop Industrie

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU for children two to 11 years of age is...